While Merck Co’s drug, Januvia, has been making headlines for its possible connection to cases of acute pancreatitis, Market Watch reports that European Union regulators have approved a new drug in the same class of DPP-4 inhibitors. Astra Zeneca PLC and Bristol-Myers Squibb Co’s drug, Onglyza, also known as saxagliptin, was approved by US regulators earlier this year. Onglyza is a once a day pill that treats Type 2 diabetes. It is approved for use in combination with metformin, sulphonylurea, or thiazolidinedione, when those drugs on their own are not effective in improving blood glucose levels.
cross-posted on A Sweet Life
Jessica Apple
Jessica Apple is the co-creator and editor of the online magazine, A Sweet Life, www.asweetlife.org. Her work has appeared in the New York Times Magazine, The Financial Times Magazine, The Southern Review, the Bellevue Literary Review, Tablet Magazine, and elsewhere. She ...
Read more about Jessica Apple ->
